Citi lowered the firm’s price target on Johnson & Johnson (JNJ) to $180 from $185 but keeps a Buy rating on the shares. The firm is updating its model after the company’s closed acquisition of Shockwave Medical (SWAV) on May 31 as the management has shared that it expects the acquisition to be $0.10 EPS dilutive in 2024, $0.17 dilutive in 2025, and accretive in 2026, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Tela Bio appoints Jeffrey Blizard to its board of directors
- J&J ordered to pay woman $260M in Oregon talc trial, Reuters says
- Needham medtech/diagnostic analyst holds analyst/industry conference call
- Johnson & Johnson reports results from subgroup analysis of CARTITUDE-4 study
- Sarepta to replace ShockWave Medical in S&P 400 at open on 6/3